Synthesis and evaluation of fluorine-18 labelled compounds for imaging of bacterial infections with pet

Applied Radiation and Isotopes

Volumn 64, Issue 7, 2006, Pages 802-807

  Zijlstra, S ^a   Gunawan, J ^a   Freytag, C ^a   Burchert, W ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; BINDING ENERGY; DISEASE CONTROL; MEDICAL IMAGING; SYNTHESIS (CHEMICAL);

BACTERIAL INFECTIONS; CHINOLINCARBOXYLIC ACID; RADIOCHEMICAL YIELD; SPECIFIC BINDING;

FLUORINE;

4 FLUOROBENZOYLUBIQUICIDIN 29-41 F 18; 6 FLUORO 1,4 DIHYDRO 1 CYCLOPROPYL 4 OXO 7 (4 FLUOROPHENACYL 1 PIPERACINYL)CHINOLINCARBOXYLIC ACID F 18; FLUORINE 18; FLUORINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL INFECTION; BIOLOGICAL ACTIVITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG BINDING; DRUG SCREENING; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUORINE RADIOISOTOPES; MAGNETIC RESONANCE SPECTROSCOPY; PIPERAZINES; QUINOLONES; RADIOPHARMACEUTICALS; RIBOSOMAL PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STAPHYLOCOCCAL INFECTIONS;

EID: 33646698667     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2006.02.095     Document Type: Article

References (23)

1. 99mTc-labeled antimicrobial peptide Ubiquicidin (29-41) accumulates less in Escherichia coli infection than in Staphlococcus aureus infection. J. Nucl. Med. 45 (2004) 849-856
2. Akhtar M.S., Qaisar A., Irfanullah J., Iqbal J., Khan B., Jehangir M., Nadeem M.A., Khan M.;A., Afzal M.S., ul-Hag I., and Imran M.B. Antimicrobial peptide 99mTc-Ubiquicidin 29-41 as human infection-imaging agent: clinical trial. J. Nucl. Med. 46 (2005) 567-573
3. Appelboom T., Emery P., Tant L., Dumarey N., and Schoutens A. Evaluation of technetium-99m-ciprofloxacin (infecton) for detecting sites of inflammation in arthritis. Rheumatology 42 (2003) 1179-1182
4. 99mTc-ciprofloxacin (Infecton). J. Clin. Pathol. 11 (2002) 817-823
5. Dumarey N., Blocklet D., Appelboom T., Tant L., and Schoutens A. Infecton is not specific for bacterial osteo-articular infective pathology. Eur. J. Nucl. Med. 29 (2002) 530-535
6. Easmon C.S.F., Crane J.P., and Blowers A. Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies. J. Antimicrob. Chemother. 18 suppl D (1986) 43-48
7. 99mTc-UBI specificity for bacteria. Nucl. Med. Biol. 30 (2003) 597-603
8. Foroumadi A., Emami S., Davood A., Moshafi M.H., Sharifian A., Tabatabaie M., Farimani H.T., Sepehri G., and Shafiee A. Synthesis and in-vitro antibacterial activities of N-substituted Piperazinyl Quinolones. Pharm. Sci. 3 (1997) 559-563
9. Hooper D.C., Wolfson J.S., Ng E.Y., and Schwartz M.N. Mechanisms of action of and resistance to ciprofloxacin. Am. J. Med. 82 Suppl. 4a (1987) 12-20
10. Hwang D.-R., Feliu A.L., Wolf A.P., MacGregor R.R., Fowler J.S., and Arnett C.D. Synthesis and evaluation of fluorinated derivatives of fentanyl as candidates for opiate receptor studies using positron emission tomography. J. Label. Comp. Radiopharm. XXIII 3 (1986) 277-292
11. Kondo H., Sakamoto F., Kodera Y., and Tsukamoto G. studies on prodrugs. 5. Synthesis and antimicrobial activity of N-(oxoalkyl)norfloxacin derivatives. J. Med. Chem. 29 (1986) 2020-2024
12. Langer O., Mitterhauser M., Brunner M., Zeitlinger M., Wadsak W., Mayer B.X., Kletter K., and Müller M. Synthesis of fluorine-18 labeled Ciprofloxacin for PET studies in humans. Nucl. Med. Biol. 30 (2003) 285-291
13. 18F]ciprofloxacin for the imaging of bacterial infections with PET. Eur. J. Nucl. Med. Mol Imaging 32 (2005) 143-150
14. 99m-Tc-Ciprofloxacin scintigraphy in a rabbit model of Staphylococcus aureus prosthetic joint infection. J. Nucl. Med. 43 (2002) 239-245
15. Toretsky J., Levenson A., Weinberg I.N., Tait J.F., Üren A., and Mease R.C. Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death. Nucl. Med. Biol. 31 (2004) 747-752
16. Welling M.M., Nibbering P.H., Paulsma-Annema A., Hiemstra P.S., Pauwels E.K.J., and Calame W. Reply to the comments of Briton et al. J. Nucl. Med. 41 (2000) 2100-2102
17. 99mTc-labeled Antimicribiol peptides for detection of bacterial and cadida albicans infections. J. Nucl. Med. 42 (2001) 788-794
18. 99mTc-UBI 29-41 for imaging of bacterial infections. Nucl. Med. Biol. 29 (2002) 413-422
19. Wester, H.J., 1996. Zur praktisch trägerfreien 18F-Fluorierung von Proteinen, Peptiden und Tyrosin. Berichte des Forschungszentrums Jülich. 3206. Dissertation, University of Cologne, Germany.
20. Wester H.J., Hammacher K., and Stöcklin G. A comparative study of n.c.a. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl. Med. Biol. 23 (1996) 365-372
21. Wilson A.P.R., and Grüneberg R.N. Ciprofloxacin: 10 Years of Clinical Experience (1997), Maxim Medical, Oxford, UK
22. Yapar Z., Kibar M., Yapar A.F., Togrul E., Kayaselcuk U., and Sarpel Y. The efficacy of technetium-99m-ciprofloxacin (Infecton) imaging in suspected orthopaedic infection: a comparison with sequential bone/gallium imaging. Eur. J. Nucl. Med. 28 (2001) 822-830
23. Zijlstra S., Gunawan J., and Burchert W. Synthesis and evaluation of a Fluorine-18 labeled recombinant Annexin-V derivative, for identification and quantification of apoptotic cells with PET. Appl. Radiat. Isot. 58 (2003) 201-207